These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

918 related items for PubMed ID: 18711173

  • 1. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
    Schetelig J, van Biezen A, Brand R, Caballero D, Martino R, Itala M, García-Marco JA, Volin L, Schmitz N, Schwerdtfeger R, Ganser A, Onida F, Mohr B, Stilgenbauer S, Bornhäuser M, de Witte T, Dreger P.
    J Clin Oncol; 2008 Nov 01; 26(31):5094-100. PubMed ID: 18711173
    [Abstract] [Full Text] [Related]

  • 2. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W, Cooperative German Transplant Study Group.
    J Clin Oncol; 2003 Jul 15; 21(14):2747-53. PubMed ID: 12860954
    [Abstract] [Full Text] [Related]

  • 3. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
    Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR, Stein RS, Bociek G, Greer JP, Wu CD, Kollath JP, Weisenburger DD, Kessinger A, Wolff SN, Armitage JO, Bishop MR.
    Bone Marrow Transplant; 2000 Apr 15; 25(7):717-22. PubMed ID: 10745256
    [Abstract] [Full Text] [Related]

  • 4. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP.
    Biol Blood Marrow Transplant; 2006 Oct 15; 12(10):1056-64. PubMed ID: 17084369
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
    Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenberghe E, Mackinnon S, Chakraverty R.
    Br J Haematol; 2013 Mar 15; 160(5):640-8. PubMed ID: 23293871
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
    Toze CL, Shepherd JD, Connors JM, Voss NJ, Gascoyne RD, Hogge DE, Klingemann HG, Nantel SH, Nevill TJ, Phillips GL, Reece DE, Sutherland HJ, Barnett MJ.
    Bone Marrow Transplant; 2000 Mar 01; 25(6):605-12. PubMed ID: 10734294
    [Abstract] [Full Text] [Related]

  • 11. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia.
    Doney KC, Chauncey T, Appelbaum FR, Seattle Bone Marrow Transplant Team.
    Bone Marrow Transplant; 2002 May 01; 29(10):817-23. PubMed ID: 12058231
    [Abstract] [Full Text] [Related]

  • 12. [Allogeneic transplantation in malignant lymphoma].
    Stötzer OJ, Schleuning M, Ledderose G, Hiddemann W, Kolb HJ.
    Dtsch Med Wochenschr; 2001 Sep 28; 126(39):1062-9. PubMed ID: 11602913
    [Abstract] [Full Text] [Related]

  • 13. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.
    Biol Blood Marrow Transplant; 2006 Jul 28; 12(7):703-11. PubMed ID: 16785059
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
    Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringdén O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C.
    J Clin Oncol; 2005 Aug 20; 23(24):5788-94. PubMed ID: 16043827
    [Abstract] [Full Text] [Related]

  • 16. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.
    Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J.
    Bone Marrow Transplant; 2005 Nov 20; 36(9):825-30. PubMed ID: 16151430
    [Abstract] [Full Text] [Related]

  • 17. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.
    Biol Blood Marrow Transplant; 2009 Nov 20; 15(11):1376-85. PubMed ID: 19822296
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
    Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S.
    J Clin Oncol; 2005 Dec 20; 23(36):9387-93. PubMed ID: 16314618
    [Abstract] [Full Text] [Related]

  • 19. Reduced intensity conditioning allogeneic transplant for advanced chronic lymphocytic leukemia.
    Soligo D, Motta M, Borsotti C, Ibatici A, Cortelezzi A, Lambertenghi Deliliers G.
    Haematologica; 2004 Jul 20; 89(7):885-6. PubMed ID: 15257953
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan 20; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.